FEGCG/Zn not only significantly modulates PD-L1 expression but also enhances the transport of immune biomolecules by forming biomimetic nanoassemblies, offering a flexible and promising platform for cancer immunotherapy [52]. The gene discussed is CD274; the disease is cancer.